摘要
目的：分析新辅助化疗前后结肠癌组织中CD44V6及p21蛋白的表达差异，并探讨新辅助化疗对结肠癌患者手术及预后的影响。方法选择滨州市中心医院2009年1月至2011年12月收治的结肠癌患者60例，将其随机分为对照组及观察组，各30例。对照组采用常规手术结合术后常规化疗的治疗方案，观察组患者在对照组治疗的基础上行术前新辅助化疗。对比分析两组患者术中检出淋巴结阳性率、术后复发率及3年生存率。结果对照组患者化疗前后CD44V6及p21蛋白表达差异不显著；而观察组患者两种蛋白的阳性率差异具有统计学意义（P〈0.05）。观察组结肠癌患者3年内存活率（70.00%）显著高于对照组患者存活率（46.67%），两组比较差异具有统计学意义（P〈0.05）。结论新辅助化疗能够显著降低结肠癌组织中CD44V6的表达，提高p21的表达，提示新辅助化疗在改善结肠癌患者的预后、提高患者生存率方面具有重要意义，可以在临床上推广应用。
Objective To analyze the effect of neoadjuvant chemotherapy on the expression of CD44V6,p21 in Patients with Colon Cancer. Methods From January 2009 to December 2011,60 patients with advanced colorectal cancer were randomly divided into experimental group and control group in Binzhou Central Hospital,the patients in control group were given general drug chemotherapy, the patients in experimental group were given the neoadjuvant chemotherapy on the basis of general drug chemotherapy.the incidence of cancer recurrence and the expression of CD44V6,p21 of the two groups were observed. Results The expression of CD44V6 or p21 in the control group were not significantly different before and after chemotherapy,while in the experimental group,the expression of CD44V6 or p21 were significantly different before and after chemotherapy. The 3-year survival in the experimental group（70.00%） was significantly higher than that in the control group（46.67%）,there were significant differences（P〈0.05）. Conclusions Neoadjuvant chemotherapy has a significant impact on the expression of CD44V6 and p21, indicates that it may may play an important role in monitoring for the judgment of prognosis and can be used for clinics.
出处
《中国临床实用医学》
2015年第3期25-27,共3页
China Clinical Practical Medicine
基金
滨州医学院科技计划项目（BY2013KJ91）
